Table 1.
Baseline data from five-blinded trials of vertebroplasty. Trials are arranged in increasing order of fracture age at time of vertebroplasty
| Trial | No. (n) | Age (years) | BMD T-score | Fracture age (weeks) | Early vertebroplasty (%) | Inpatients (%) | PMMA (ml) |
|---|---|---|---|---|---|---|---|
| VAPOUR | 120 | 80 | − 4.3 | 2.6 | 79 | 57 | 7.5 |
| VERTOS4 | 180 | 75 | − 2.4 | 6 | 19 | 0 | 5.1 |
| Hansen | 46 | 70 | − 2.4 | NR | NR | 0 | NR |
| Buchbinder | 78 | 74 | NR | 12 | NR | 0 | 2.8 |
| Kallmes | 131 | 73 | NR | 18 | 0 | 0 | 2.6 |
Early vertebroplasty = the percentage of vertebroplasty patients who received vertebroplasty within 3 weeks of fracture. Inpatients = the proportion of patients who were already hospitalised at the time of enrolment. PMMA volume = the amount of PMMA injected per treated fracture. Age, BMD, fracture age and PMMA volume are mean measurements. NR indicates that these data were not reported
BMD bone mineral density expressed as T-score